Pro members get same-minute coverage on the stocks they track. Free plans update twice a day.
Get ProCounts of positive, neutral, and negative news items. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
The items moving the net sentiment the most, by direction and influence.
Sun Pharma Stock: FY26 Revenue at Rs 58,462 Crore as Organon Acquisition Plan Emerges
Direct news · High influence · Long term
Sun Pharma Wins South Africa Approval for Generic Ozempic
Direct news · Medium influence · Long term
Sun Pharma's Organon Financing Deal Draws SBI Into Global Lender Group
Direct news · Medium influence · Long term
Sun Pharma FY26 Revenue Climbs 11.9% to About Rs 58,220 Crore
Direct news · Medium influence · Long term
US Cancer Drug Shortage Creates Generic Supply Window for Sun Pharma and Dr Reddy's
US FDA / USFDA · Medium influence · Short term
Macro, commodity, FX and regulatory forces that moved SUNPHARMA in this range, with the stories behind each.
Sign up free to track SUNPHARMA, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track SUNPHARMA for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
Sun Pharma's Organon Financing Deal Draws SBI Into Global Lender Group
How news sentiment on Sun Pharmaceutical Industries Ltd. (SUNPHARMA) has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
